CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 306 enrolled
Drug / intervention
Bevacizumab [Avastin] +2 moredrug
Likely dose
Bevacizumab [Avastin] 7.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01131078
NCT01131078Phase 2Completed
CompareCT.gov

A Randomized, Open-label Study Comparing the Effect of 3 Chemotherapy Regimens Containing Avastin on Time to Disease Progression in Patients With Metastatic Colorectal Cancer

Hoffmann-La Roche·interventional·Posted May 26, 2010·Updated Jun 4, 2015

In Brief

A Phase 2 clinical trial evaluating Bevacizumab [Avastin], Capecitabine, and 1 other intervention for Colorectal Cancer. Completed, enrolled 306 participants across 44 sites.

Detailed Summary

A study of Avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. The anticipated time on study treatment is until disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2010
Enrollment StartJun 1, 2005
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 16.1 years ago

Interventions

Bevacizumab [Avastin]drug

Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.

Capecitabinedrug

Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.

Irinotecandrug

Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.